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ORIGINAL ARTICLE
Mice deleted for cell division cycle 73 gene develop parathyroid
and uterine tumours: model for the hyperparathyroidism-jaw
tumour syndrome
GV Walls1, M Stevenson1, KE Lines1, PJ Newey1, AAC Reed1, MR Bowl1, J Jeyabalan1, B Harding1, KJ Bradley1, S Manek2, J Chen3,
P Wang3, BO Williams4, BT Teh3 and RV Thakker1
The hyperparathyroidism-jaw tumour (HPT-JT) syndrome is an autosomal dominant disorder characterized by occurrence of
parathyroid tumours, often atypical adenomas and carcinomas, ossifying jaw ﬁbromas, renal tumours and uterine benign and
malignant neoplasms. HPT-JT is caused by mutations of the cell division cycle 73 (CDC73) gene, located on chromosome 1q31.2 and
encodes a 531 amino acid protein, paraﬁbromin. To facilitate in vivo studies of Cdc73 in tumourigenesis we generated conventional
(Cdc73+/− ) and conditional parathyroid-speciﬁc (Cdc73+/L/PTH-Cre and Cdc73L/L/PTH-Cre) mouse models. Mice were aged to 18-21
months and studied for survival, tumour development and proliferation, and serum biochemistry, and compared to age-matched
wild-type (Cdc73+/+ and Cdc73+/+/PTH-Cre) littermates. Survival of Cdc73+/− mice, when compared to Cdc73+/+ mice was reduced
(Cdc73+/− = 80%; Cdc73+/+= 90% at 18 months of age, Po0.05). Cdc73+/− , Cdc73+/L/PTH-Cre and Cdc73L/L/PTH-Cre mice developed
parathyroid tumours, which had nuclear pleomorphism, ﬁbrous septation and increased galectin-3 expression, consistent with
atypical parathyroid adenomas, from 9 months of age. Parathyroid tumours in Cdc73+/− , Cdc73+/L/PTH-Cre and Cdc73L/L/PTH-Cre
mice had signiﬁcantly increased proliferation, with rates4fourfold higher than that in parathyroid glands of wild-type littermates
(Po0.0001). Cdc73+/− , Cdc73+/L/PTH-Cre and Cdc73L/L/PTH-Cre mice had higher mean serum calcium concentrations than wild-type
littermates, and Cdc73+/− mice also had increased mean serum parathyroid hormone (PTH) concentrations. Parathyroid tumour
development, and elevations in serum calcium and PTH, were similar in males and females. Cdc73+/− mice did not develop bone
or renal tumours but female Cdc73+/− mice, at 18 months of age, had uterine neoplasms comprising squamous metaplasia,
adenoﬁbroma and adenomyoma. Uterine neoplasms, myometria and jaw bones of Cdc73+/− mice had increased proliferation rates
that were 2-fold higher than in Cdc73+/+ mice (Po0.05). Thus, our studies, which have established mouse models for parathyroid
tumours and uterine neoplasms that develop in the HPT-JT syndrome, provide in vivo models for future studies of these tumours.
Oncogene (2017) 36, 4025–4036; doi:10.1038/onc.2017.43; published online 13 March 2017
INTRODUCTION
Mutations of the cell division cycle 73 (CDC73) gene (OMIM
#607393), which is located on chromosome 1q31.2 and encodes a
531 amino acid protein called paraﬁbromin, are associated with
hereditary and non-hereditary forms of parathyroid carcinomas
and the hyperparathyroidism-jaw tumour (HPT-JT) syndrome
(OMIM #145001).1–3 HPT-JT, an autosomal dominant disorder, is
characterized by the occurrence of parathyroid tumours, and
ossifying ﬁbromas of the jaw which occur in ~ 30% of HPT-JT
patients (Table 1).1,4–6 The parathyroid tumours are usually
parathyroid adenomas (PAs) but may be atypical parathyroid
adenomas (APAs) or parathyroid carcinomas (PCs) in 415% of
HPT-JT patients. In addition, 415% of HPT-JT patients may also
develop renal tumours, which include Wilms’ tumours, hamarto-
mas and carcinomas, and ~ 75% of women with HPT-JT will
develop, at an early age, benign and malignant neoplasms of the
uterus that may be associated with recurrent miscarriages and
severe menorrhagia, requiring hysterectomy.4,5,7–9 These uterine
neoplasms which all arise in cells derived from the embryonic
mesodermal Mullerian duct system, comprise extensive adeno-
myosis, adenoﬁbromas, endometrial hyperplasia, leiomyosis and
adenosarcomas in ~ 55%, ~ 35%, ~ 30%, ~ 30% and ~ 15% of
patients, respectively, and women with HPT-JT, may have more
than one type of uterine neoplasm (Table 1). Other tumours that
may arise in o2% of HPT-JT patients are Hürthle cell thyroid
adenomas, pancreatic adenocarcinomas and mixed germ cell
testicular tumours.4,5,7,8 CDC73 loss of heterozygosity (LOH) has
been observed in HPT-JT associated tumours, thereby indicating a
likely tumour suppressor role for CDC73.1 A tumour suppressor
role for CDC73 is further supported by reports that the majority of
CDC73 mutations are predicted to result in a functional loss of
paraﬁbromin, and that some HPT-JT tumours and non-hereditary
PCs harbour both germline and somatic mutations, consistent
with the Knudson 'two-hit' hypothesis.10–12
Paraﬁbromin, which is encoded by exons 1–17 of CDC73
(Figure 1a), is a ubiquitously expressed predominantly nuclear
protein that is evolutionary conserved.1 Moreover, the ~ 200
amino acids of the terminal segment of paraﬁbromin have ~ 27%
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sequence identity and 47% similarity to the yeast Cdc73 protein,
which is a component of the polymerase-associated factor-1 (Paf1)
complex,13 a key transcriptional regulatory complex that interacts
directly with RNA polymerase II. The crystal structure of the yeast
Cdc73 C-domain has been reported to adopt a Ras-like fold that
participates in histone ubiquitination and methylation steps
through both promoter and coding regions, and studies have
shown that human homologues of the yeast Paf1 complex are
associated with paraﬁbromin.14–16 Moreover, paraﬁbromin and its
Drosophila homologue, Hyrax, which is a component of the Wnt1
wingless pathway and has an essential role in normal embryonic
development, have a high degree of sequence similarity in their
C-terminal portions.17,18 This suggested that paraﬁbromin may
have a role in embryonic development and studies of mice
deleted for Cdc73 have also shown that paraﬁbromin has key roles
in mammalian embryonic development.19 Thus, Cdc73 null mice
were embryonic lethal by 6.5 day post-coitum, which is the stage
when implantation occurs.19 Paraﬁbromin and Hyrax also have a
high degree of sequence similarity in their N-terminal domains,
which directly interact with β-catenin/Armadillo in the context of
the PAF1 complex.17 The role of paraﬁbromin as a mediator of
Wnt signalling is supported by studies in human HEK293 cells,
which has shown that Wnt target gene expression is directly
correlated with paraﬁbromin expression.17 Moreover, paraﬁbro-
min overexpression in HEK293 and NIH3T3 cells strongly inhibits
proliferation, and in HeLa cells it increases G1 phase arrest and
apoptosis with a concomitant reduction in S-phase entry, and a
resulting downregulation of the cell cycle regulator cyclin D1,
which is an oncogene known to be upregulated in parathyroid
tumours.19–21 Furthermore, underexpression of paraﬁbromin,
induced by RNAi, has been reported to increase the proportion
of HeLa cells in S-phase, and to reduce basal apoptosis.13 These
in vitro ﬁndings indicate that paraﬁbromin is a likely tumour
suppressor in mammalian cells, and to explore further the role of
paraﬁbromin as an in vivo tumour suppressor we studied mice
deleted for Cdc73 for the development of tumours.
RESULTS
Generation, viability and survival of mice deleted for Cdc73 alleles
Conventional Cdc73 knockout mice were established using the
embryonic stem (ES) cell line (RRE190) from Bay Genomics
Genetrap resource (Figure 1a),22 as described,19 and congenic
animals obtained by backcrossing onto wild-type C57BL/6 females
for ten generations. Expression of wild-type and mutant Cdc73
and paraﬁbromin, was detected by RT-PCR (Figure 1b) and
western blot analysis (Figure 1c), respectively, to establish the
wild-type (Cdc73+/+) and heterozygote (Cdc73+/Gt(RRE190)Byg,
referred to as Cdc73+/− ) genotypes of adult mice. Cdc73+/− mice
were viable and fertile and homozygote (Cdc73Gt(RRE190)Byg/Gt(RRE190)Byg,
referred to as Cdc73-/-) mice have been previously reported to
demonstrate embryonic lethality.19 Kaplan–Meier analysis of 284
mice, comprising 104 Cdc73+/+ mice (n= 36 male, 68 female) and
180 Cdc73+/− mice (n= 72 male, 108 female) aged to 18 months,
revealed a signiﬁcantly decreased survival of Cdc73+/− mice
compared to Cdc73+/+ mice (survival of Cdc73+/− versus Cdc73+/+
mice = 80% versus 90%, Figure 2a, Po0.05). Further analysis of
this data by gender, revealed that the decreased survival of
Cdc73+/− mice was largely due to decreased survival of male
Cdc73+/− mice, which was observed from 7 months of age
(Figure 2b); the survival of Cdc73+/+ male and female mice was
similar (Figure 2c). The decreased survival in male Cdc73+/− mice
was not associated with lower bodyweight (Figure 2d), which was
consistent with the reported mean bodyweight for C57BL/6 mice
of similar ages.23
Parathyroid-speciﬁc Cdc73 conditional knockout mice, were
generated by mating parathyroid hormone (PTH)-Cre transgenic
mice24 with previously established Cdc73-ﬂoxed mice (Cdc73L/L).19
This resulted in mice deleted for one or both Cdc73 alleles in the
parathyroids, that yielded heterozygote Cdc73+/L/PTH-Cre and
homozygote Cdc73L/L/PTH-Cre mice, respectively,19,24 which were
viable and fertile. A total of 52 parathyroid-speciﬁc Cdc73 knockout
mice were generated, and comprised 20 Cdc73+/+/PTH-Cre mice,
15 Cdc73+/L/PTH-Cre mice and 17 Cdc73L/L/PTH-Cre mice.
Examination for development of HPT-JT associated tumours.
Development of HPT-JT associated tumours was assessed in 69
mice (21 Cdc73+/+ mice (9 males and 12 females) and 48 Cdc73+/−
conventional knockout mice (12 males and 36 females)) between
the ages of 47 to o24 months (Table 1). Parathyroid tumours
were found to occur in 68% of Cdc73+/− mice, and 25% of these
were adenomas and 75% were APAs (deﬁned by having
collagenous ﬁbrous septa,25 and/or immunostaining for galectin-
3 but lacking evidence of invasion or metastasis). We used
immunostaining for galectin-3, which is an anti-apoptotic lectin
that regulates cyclin D1 and C-Jun N-terminal kinase 1 (JNK1)
expression and promotes tumour growth and metastasis,26,27 as it
has been reported to have a sensitivity of495% and speciﬁcity of
90% for pathological diagnosis of PC in man.28,29 Uterine
neoplasms were found in ~ 33% of Cdc73+/− females (Table 1).
Parathyroid tumours or uterine neoplasms were not found to
occur in Cdc73+/+ mice. Ossifying ﬁbromas of the jaw, and tumours
of the kidneys, thyroid, pancreas or testis (Table 1) were not found
in any of the Cdc73+/− or Cdc73+/+ mice. Parathyroid tumour
development was also found to occur in 440% of the 32
conditional knockout mice, which comprised 15 Cdc73+/L/PTH-Cre
mice (9 males and 6 females) and 17 Cdc73L/L/PTH-Cre mice (8
males and 9 females), but not in any of 20 Cdc73+/+/PTH-Cre mice
(11 males and 9 females), aged 20–21 months of age. The
parathyroid and uterine neoplasms developing in the mutant
mice were further studied.
Analysis of parathyroid tumours
Parathyroid glands were identiﬁed in 74% of mice (n= 109) and
the remaining 26% of mice in whom parathyroid glands were not
identiﬁed were evenly distributed among all the genotypes.
Parathyroid tumours were found in 465% of Cdc73+/− mice
(n= 15/22) but in none of 16 Cdc73+/+ littermates (Po0.0001, two-
tailed Fisher’s exact test, Table 1), between 9 and 18 months of
age; and in ⩾ 50% of ⩾ 18-month-old Cdc73+/L/PTH-Cre (n= 7/12)
Table 1. Proportion of tumours (percent) in patients with the
hyperparathyroidism-jaw tumour (HPT-JT) syndrome and Cdc73+/−
mice
Tumour HPT-JT patients Cdc73+/− mice
(⩾ 18 months)
Parathyroid 82% adenoma (108/132)1
415% carcinoma (20/132)1,9
68% overall
25% adenoma
75% atypical adenoma
Mandible 33% ossifying ﬁbroma (67/205)9 0%
Uterus 74% overall (20/27)7,9
53% adenomyosis (8/15)
33% adenoﬁbroma (5/15)
27% endometrial hyperplasia (4/15)
27% leiomyoma (4/15)
13% adenosarcoma (2/15)
33% overall
100% endometrial cysts
25% endometrial
hyperplasia
13% adenoﬁbroma
13% adenomyoma
Kidney 16% hamartoma (21/132)5
o2% Wilms' tumour (3)4
0%
Thyroid o2% Papillary thyroid
carcinoma (2)7
o1% Hurthle cell adenoma (1)8
0%
Pancreas o1% Adenocarcinoma (1)8 0%
Testis o1% Mixed germ cell tumour (1)8 0%
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and Cdc73L/L/PTH-Cre (n= 6/12) mice, but not in any of 19
Cdc73+/+/PTH-Cre littermates (Po0.005). The parathyroids in
wild-type mice were ~ 500 μm in length (Supplementary
Figure 2) and had a homogenous appearance (Figure 3a).
Parathyroid tumours (Figures 3b–d), which were ~ 1 mm in length
(Supplementary Figure 2) and had a heterogenous architecture,
developed in Cdc73+/− , and Cdc73+/L/PTH-Cre and Cdc73L/L/PTH-
Cre mice, and these demonstrated abnormalities that included
glandular enlargement, nuclear pleomorphism, and septation
(Figures 3b–d), which are features often observed in PCs and
APAs. Indeed 75% of the parathyroid tumours of Cdc73+/− ,
Cdc73+/L/PTH-Cre and Cdc73L/L/PTH-Cre mice, when compared to
wild-type littermates had features found in APAs (Table 1),1,9 that
included: increased collagen deposition in the septa (Figures 3e–
h); reduced nuclear expression of paraﬁbromin (Figures 3i–l); and
increased expression of galectin-3 (Figures 3m–p). Loss of
Figure 1. Establishing a conventional Cdc73 knockout mouse model. (a) Schematic diagram of the Cdc73 gene representing the wild-type (WT,
+) and recombinant (R, − ) alleles. ATG and TGA represent the start and stop codons respectively. The exons are represented by boxes (open
boxes depict translated regions), and the domains within the GeneTrap (Gt) vector, incorporated into the R allele, are labelled. The GeneTrap
vector in the RRE190 ES cells from BayGenomics22 referred to as Gt(RRE190Byg) is inserted into intron 6 of the Cdc73 gene and subsumes normal
splicing of the Cdc73 exon 6 donor site to the GeneTrap Engrailed2 (EN2) acceptor site with loss of exons 7–17. Thus, the paraﬁbromin-β-geo
fusion from the ﬁrst six exons of the Cdc73 gene, would contain only the N-terminal 170 amino acids, which encompasses the nuclear
localization signal, and lack the remaining 361 amino acids which will encompass the domains that interact with the Paf1 complex, histone
methyltransferase complexes,16 and β-catenin,17 of the wild-type paraﬁbromin. A loss of these critical domains would render the expressed
mutant paraﬁbromin non-functional. LoxP (locus of crossing over in phage P1), Lox71 (locus of crossing over 71), FRT (ﬂippase recognition
target), SA (splice acceptor of mouse), βGeo (EN2 exon 2, fusion of β-galactosidase and neomycin transferase), IRES (internal ribosome entry
site), PLAP (placental alkaline phosphatase) and SV40pA (Simian virus 40 polyadenylation signal). The Lox71, LoxP and FRT sites, located in the
GeneTrap vector allow the capability to remove the engrailed intron and β-geo, by breeding with Cre or Flp expressing mice, in order to
restore gene function. However, this was not undertaken for this study. (b) Identiﬁcation of wild-type (Cdc73+/+) and heterozygous (Cdc73+/− )
mice by RT–PCR using template RNA extracted from kidneys of adult mice and primers (3 f, 9r and rev). The sizes of the wild-type (WT) and
mutant (M) bands are 593 and 500 bp, respectively. (c) Western blot analysis of kidney lysates from adult Cdc73+/+ and Cdc73+/− mice, utilizing
an anti-β-geo antibody, revealed the expression of a paraﬁbromin/beta-geo fusion protein (169 kDa) in Cdc73+/− knockout mice only.
(d) Analysis of paraﬁbromin expression (64 kDa) using an anti-paraﬁbromin antibody (A300-171A) revealed a 50% reduction in expression
assessed by densitometry of band intensity normalized for GAPDH expression (n= 4) in Cdc73+/− mice compared to Cdc73+/+ mice; the whole
Western blot is shown. The speciﬁcity of the anti-paraﬁbromin antibody was validated in HeLa cells transfected with siRNA against CDC73
(Supplementary Figure 1). These results also show that only one form of paraﬁbromin of size 64 kDa and representing the 531 amino acid
protein is expressed by Cdc73, despite the reports of of 6 Cdc73 transcripts in the Ensembl database.75 These 6 murine Cdc73 transcripts
comprise: transcript 1 which is 11586 bp and encodes a 531 amino acid protein; transcripts 2, 4, 5 and 6 which are 3134 bp, 3056 bp, 2727 bp
and 1047 bp, respectively, in length and are processed transcripts or retained introns that do not lead to protein products; and transcript 3
that is 479 bp in length and results in a 73 amino acid protein and subject to nonsense mediated decay. Thus, the observation of only one
form of paraﬁbromin of 64 kDa, is consistent with the translation of transcript 1 in the Ensembl database,75 which results in the 531 amino acid
paraﬁbromin. The 37 kDa bands, which do not correspond to any translated proteins from the other transcripts, are present with similar
intensities in Cdc73+/− and Cdc73+/+ mice (P= 0.493, n= 4), and are likely to represent non-speciﬁc bands. Such non-speciﬁc bands, which were
not altered by the use of CDC73 siRNA (siCDC73), were also detected in HeLa cells (Supplementary Figure 1). B, blank; F, female; M, male;
RTase, reverse transcriptase; S, size marker.
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retinoblastoma protein expression and increased cyclin D1
expression, which are found in 495% and 90%30 of human PCs,
respectively, were not found to occur in the parathyroid tumours
from Cdc73+/− , Cdc73+/L/PTH-Cre and Cdc73L/L/PTH-Cre mice (data
not shown). To assess the proliferation rate of these parathyroid
tumours, mice were given the thymidine analogue BrdU in
drinking water for two weeks,31 and the proportion of cells that
had incorporated nuclear BrdU was calculated (Figures 3q–t,
Table 2). The parathyroid tumours developing in the Cdc73+/− and
Cdc73+/L/PTH-Cre mice had signiﬁcantly higher daily proliferation
rates, by three- to fourfold, while that of Cdc73L/L/PTH-Cre mice
was ~ 9-fold higher, when compared to those of parathyroid
glands in wild-type mice Cdc73+/+ and Cdc73+/+/PTH-Cre mice
(Table 2, Po0.0001). Apoptotic rates in parathyroids of Cdc73+/− ,
Cdc73+/L/PTH-Cre and Cdc73L/L/PTH-Cre mice were not signiﬁcantly
different from wild-type (Cdc73+/+ and Cdc73+/+/PTH-Cre) littermates
(Figures 3u–x, Supplementary Figure 4).
Parathyroid tumours in the Cdc73+/− (n= 25, age417 months),
when compared to similarly aged wild-type Cdc73+/+ littermates
(n= 20), were associated with increased mean ( ± s.e.m.) serum
calcium concentrations (Cdc73+/− versus Cdc73+/+=2.85±0.04 mmol/l
versus 2.66 ± 0.08 mmol/l, Po0.05, Figure 4a), that was accom-
panied by a signiﬁcantly increased mean (± s.e.m.) serum
parathyroid hormone (PTH) concentration (Cdc73+/− versus
Cdc73+/+ =81.34±10.29 pmol/l, versus 52.03±7.43 pmol/l, Po0.05,
Figure 4b). The serum phosphate (Figure 4c), creatinine (data not
shown) and albumin concentrations (data not shown) were not
statistically different between Cdc73+/−and Cdc73+/+mice aged
17-24 months, and Cdc73+/−and Cdc73+/+mice ⩽ 12 months of
age had no statistical differences in serum calcium, adjusted for
albumin, or serum phosphate concentrations (data not shown).
Thus, Cdc73+/− mice over 17 months of age had features of
primary hyperparathyroidism. Cdc73+/L/PTH-Cre (n= 5, age
420 months) and Cdc73L/L/PTH-Cre (n= 5, age 420 months)
mice, when compared to Cdc73+/+/PTH-Cre (n= 9) littermates also
had elevated mean (±SEM) serum calcium concentrations (Cdc73+/L/
PTH-Cre= 2.81 ±0.07 mmol/l, Cdc73L/L/PTH-Cre 2.76 ± 0.08 mmol/l
and Cdc73+/+/PTH-Cre= 2.52 ± 0.07 mmol/l, Po0.01). The serum
albumin (data not shown), creatinine (data not shown) and
phosphate concentrations were not signiﬁcantly different (Cdc73+/L/
PTH-Cre= 3.27 ± 0.13 mmol/l, Cdc73L/L/PTH-Cre= 3.37 ± 0.40 mmol/l
and Cdc73+/+/PTH-Cre= 2.99 ± 0.23 mmol/l).
Analysis of uterine neoplasms
Macroscopic uterine tumours at necropsy were observed in 33.3%
(n= 8/24) of female Cdc73+/− mice, aged ⩾ 18 months, but in none
of 24 Cdc73+/+ littermates (Po0.005, two-tailed Fisher’s exact
test). Histology of ⩾ 18 month old Cdc73+/− mice demonstrated
several abnormalities, when compared to those from Cdc73+/+
littermates (Figures 5a–e). Thus, uteri from Cdc73+/+ mice had
glandular endometria with a uniform mucosal epithelium,
whereas uteri from Cdc73+/− mice had: large cysts within the
Figure 2. Survival and weights of Cdc73+/+ and conventional Cdc73+/
− knockout mice. (a) Survival of Cdc73+/+and Cdc73+/− mice (data for
male and female mice combined) over 18 months. Kaplan–Meier
analysis revealed signiﬁcantly lower survival in Cdc73+/− mice when
compared to Cdc73+/+ mice (80 versus 90%, Log-rank Mantel Cox
test, Po0.05). Moreover the reduced survival in the Cdc73+/− mice
was observed from 15 months of age (*Po0.05, Fisher’s exact test).
(b) Kaplan–Meier analysis showed that Cdc73+/− males had
signiﬁcantly reduced survival than Cdc73+/− females (Log-rank
Mantel Cox test, Po0.005), which was observed from the age of
7 months (*Po0.05, †Po0.01, Fisher’s exact test). (c) Kaplan–Meier
analysis showing that survival of male and female Cdc73+/+ mice was
similar. Moreover, the survival of Cdc73+/+ male mice did not differ
signiﬁcantly (P= 0.094) from that of Cdc73+/− male mice (see above).
(d) Bodyweights at 18 months of age of Cdc73+/+and Cdc73+/− mice,
showing that the mean bodyweights of Cdc73+/+and Cdc73+/−
males, and of Cdc73+/+and Cdc73+/− females were similar.
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endometrium (Figures 5b–e); endometrial hyperplasia with areas of
squamous metaplasia (Figures 5b–c); and bridging of the endo-
metrial lining across the uterine lumen (Figures 5b–e). Furthermore,
Cdc73+/− mice had uterine tumours which included an adenoﬁ-
broma (Figure 5d) and an adenomyoma (Figure 5e), that were not
observed in Cdc73+/+ littermates. Paraﬁbromin expression was
present in uteri of ⩾ 18 month old Cdc73+/+ mice (Figure 5f), but
was reduced in uterine tumours (for example, ﬁbroadenoma,
Figure 5g) of Cdc73+/− mice. Moreover assessment of progesterone
receptor expression, which is a favourable prognostic marker in
uterine tumours,32–35 revealed strong endometrial expression of
progesterone receptor in uteri of Cdc73+/+ mice (Figure 5h), but
absent endometrial progesterone receptor expression in all of the
hyperplastic, ﬁbroadenoma and adenomyoma lesions from
Cdc73+/− mice (Figure 5i), which instead had increased stromal
expression of progesterone receptor.
Assessment of proliferation rates, using BrdU incorporation,
revealed the myometria from Cdc73+/− mice to have a ~ 2-fold
increase in proliferation rates when compared to that of wild-type
littermates (Table 2, Po0.05). This was conﬁrmed by immuno-
staining for Ki-67, which revealed a signiﬁcantly increased
proliferation in the endometria and myometria of Cdc73+/− mice
with uterine tumours, by 1.5- and 2.5-fold, respectively, when
compared to equivalent uterine tissues of wild-type littermates
(Figures 5j–l).
Other tumours
Tumours of the bones, kidneys, thyroid, pancreas, or testes, which
may develop in HPT-JT patients, were not detected macroscopi-
cally or microscopically in Cdc73+/− mice, aged up to 21 months of
age. Jaw bones of Cdc73+/− mice had 2-fold increased prolifera-
tion rates compared to wild-type littermates (Table 2, Po0.05),
but renal and pancreatic proliferation rates were similar in Cdc73+/−
and wild-type littermates (Table 2).
DISCUSSION
The results of our study, which established mice deleted for Cdc73
alleles, reveal that these mice are representative of HPT-JT in man.
Thus, Cdc73+/− mice develop: parathyroid tumours in association
with increased mean serum calcium concentrations and increased
mean serum PTH concentrations, consistent with primary
hyperparathyroidism; and uterine neoplasms, which comprised
endometrial hyperplasia and cysts, adenoﬁbroma and adeno-
myoma. Moreover, 75% of the parathyroid tumours were APAs,
and thus these Cdc73+/− mice with the conditional Cdc73+/L/PTH-
Cre and Cdc73L/L/PTH-Cre mice provide important in vivo models
for this rare but difﬁcult to treat human neoplasm. These
parathyroid tumours and uterine neoplasms had a lack (or
reduction) of nuclear expresison of paraﬁbromin, consistent with
a tumour suppressor role for Cdc73, and similar to the ﬁndings
reported in HPT-JT associated tumours in man.36 However, there
are some differences in the frequency of tumours that develop in
the Cdc73+/− mice and patients with HPT-JT, and ﬁve of these are
as follows: (1) PAs are the commonest manifestation occuring in
480% of HPT-JT patients, whereas they occurred in only 25% of
Cdc73+/− mice, the majority of which instead had APAs with
features similar to PCs that occur in ~ 15% of HPT-JT patients
(Table 1); (2) ossifying jaw ﬁbromas occur in ~ 33% of HPT-JT
patients, but were not found in Cdc73+/− mice, which did however
have an increased mandibular cell proliferation rate; (3) uterine
adenomyosis and adenoﬁbroma which are the commonest
manifestations, occurring in 53% and 33% of women with
HPT-JT respectively, were rare (or not found) in Cdc73+/− mice,
which instead had endometrial cysts that were not observed in
women with HPT-JT; (4) renal hamartomas and Wilm’s tumour,
which occur in 415% and o2% of HPT-JT patients, were not
found in Cdc73+/− mice; and (5) thyroid cancer, pancreatic
adenocarcinoma and testicular germ cell tumours, which occur
in o2% of HPT-JT patients, were not found in Cdc73+/− mice. The
basis of these inter-species differences remain to be deﬁned but
they may be partly due to: the methods of detection, which may
have missed detecting the small tumours in the Cdc73+/− mice;
the possible later onset of tumours, as suggested by the ﬁnding of
the increased mandibular cell proliferation rate which may
represent a pre-malignant or early neoplastic phase of tumour-
igenesis; the possible functional redundancy of paraﬁbromin for
tumourigenesis in kidneys, pancreas, testes and jaw of mice; and
the effects of species-speciﬁc genetic modiﬁers that might alter
the phenotypic expression of the Cdc73 mutation in a species.
However, it is important to note that the Cdc73+/− mice
developed two of the most common tumours, namely parathyroid
tumours and uterine neoplasms that are observed in HPT-JT
patients. Thus, Cdc73+/− mice provide an in vivo model for the
study of APAs and uterine neoplasms. The development of these
tumours resulted in Cdc73+/− mice having a reduced survival
(Figure 2a). Moreover, survival of Cdc73+/− males was signiﬁcantly
less than Cdc73+/− females (Figure 2b), even though there were
no differences in mean serum calcium or PTH concentrations, or
the development of parathyroid tumours, between the genders.
The basis of the decreased survival in Cdc73+/− males remains
unknown, but a reduction in signalling via insulin-like growth
factor-1 (IGF-1), which is reported to favour female longevity in
mice,37,38 may be contributing, especially as paraﬁbromin in
murine embryonic ﬁbroblasts has been reported to bind the IGF-1
promoter, and the loss of paraﬁbromin has been observed
to decrease expression of Igf-1.19 Finally, our results, which
demonstrate that both conventional (Cdc73+/− ) and conditional
(Cdc73+/L/PTH-Cre and Cdc73L/L/PTH-Cre) knockout mice develop
parathyroid tumours, indicate that Cdc73 has a critical role in
parathyroid tumourigenesis.
PCs, which have an incidence from 0.5% to 5% of primary
hyperparathyroidism cases, may metastasize to regional lymph
nodes or distant sites such as lungs, liver, bone or pancreas, and
patients will generally die from complications of the associated
hypercalcaemia.39 The only curative treatment for PC is en bloc
resection of the primary tumour.3 However, PC cannot be easily
distinguished from APA or PA pre-operatively or intra-operatively,
in the absence of macroscopic tumour invasion or metastasis, and
thus most patients with PC do not receive curative surgery and
require long-term medical management.39 Medical therapies,
including chemotherapy and radiotherapy, are ineffective
with the exception of cinacalcet, an allosteric modulator of the
calcium-sensing receptor, which is effective in correcting the
hypercalcaemia.39 Thus, improved medical therapies for PC are
required. Paraﬁbromin immunostaining may represent an impor-
tant prognostic marker, as loss of paraﬁbromin immunostaining
has been reported to be associated with decreased disease-free
survival and tumour recurrence in patients with PCs.40,41 More-
over, APAs with loss of paraﬁbromin immunostaining are
considered tumours of uncertain malignant potential as their
recurrence rate is higher at 20% when compared to a 0%
recurrence rate in APAs that express paraﬁbromin.40,41 Thus, our
conventional and conditional Cdc73 knockout mouse models that
develop APAs lacking paraﬁbromin expression will facilitate
studies aimed at understanding the molecular pathogenesis of
APAs, PCs and PAs, and in providing pre-clinical models for
evaluating drugs.
CDC73 mutations occur in ~ 70% of patients with sporadic, non-
syndromic PCs, and in 475% of patients with HPT-JT. Indeed,
CDC73 abnormalities, either due to mutations or LOH are the
major driver for PCs in humans, although expression of a mutated
paraﬁbromin protein rather than complete loss of paraﬁbromin
expression has also been reported in some PCs.2 In addition copy
number gain of mutant CDC73 alleles, with loss of the wild-type
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CDC73 allele through focal deletion or loss of the chromosomal
arm have also been reported,42 and the roles and mechanims of
such selections of mutated CDC73 alleles in parathyroid tumour-
igenesis remains to be elucidated. Mutations involving other
genes are rare, and to date 6 multiple endocrine neoplasia type 1
(MEN1) germline mutations and 2 rearranged during transfection
(RET) germline mutations have been reported in patients with PCs
occurring in association with MEN1 and MEN2A, respectively;43–45
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and 5 Prune Homolog 2 (PRUNE2) mutations (1 germline and 4
somatic) have been reported in PCs.42 Other genetic abnormalities
that have been detected in human PCs include: retinoblastoma
(RB) loss of heterozygocity (LOH) and loss of expression (LOE) in
485% of PCs;46 cyclin D1 (CCND1) overexpression in 490% of
PCs;30 adenomatous polyposis coli (APC) LOH and LOE in ~ 75% of
PCs;47 tumour protein 53 (TP53) LOH and LOE in 33% of PCs;48
glycogen synthase kinase 3-β (GSK3β) LOE in 33% of PCs;47 and
enhancer of zeste homolog 2 (EZH2) gene ampliﬁcation in 60% of
PCs.49 Abnormalities of these genes are not necessarily associated
with PCs in mice. For example Men1+/− mice develop PAs but not
carcinomas;50 transgenic mice overexpressing cyclin D1 develop
adenomas but not carcinomas;51 Rb+/− mice develop medullary
thyroid carcinomas and pituitary adenocarcinomas but not PCs;52
and Men1+/− /Rb+/− mice developed pituitary, thyroid and
pancreatic islet hyperplasia, but not PCs.52 These ﬁndings indicate
that loss of RB expression and increase of cyclin D1 expression
may not be required for PC development in the mouse, and are
consistent with our observations that RB and cyclin D1 expression
were not altered in the APAs of Cdc73+/− mice. Moreover, these
ﬁnding indicate that Cdc73 abnormalities represent the major
driver for PCs in humans and APAs in mice.
Uterine corpus tumours, are common, occurring in 430% of
women 440 years, and may be benign or malignant.53 Uterine
tumours may originate from: the epithelial layer for example,
endometrial hyperplasia or carcinoma; the mesenchymal layers,
Table 2. Daily proliferation rates of conditional and conventional Cdc73 knockout mice, assessed by incorporation of BrdU, in parathyroid, jawbone,
kidney, pancreas and uterine tissues
Tissue Genotype Mean proliferation ratea Fold change P-value
%/day ± s.e.m. vs wild type vs Cdc73+/+
Parathyroid
Cdc73+/+ 0.150± 0.020 — —
Cdc73+/− 0.628± 0.101 4.2 0.0001
Cdc73+/+/PTH-Cre 0.165± 0.016 — 0.380
Cdc73+/L/PTH-Cre 0.513± 0.053 3.1 o0.0001
Cdc73L/L/PTH-Cre 1.416± 0.389 8.6 o0.0001
Mandible
Cdc73+/+ 0.653± 0.170 — —
Cdc73+/− 1.476± 0.254 2.3 0.014
Uterus
Myometrium Cdc73+/+ 0.526± 0.063 — —
Cdc73+/− 0.900± 0.168 1.7 0.046
Endometrium Cdc73+/+ 1.903± 0.244 — —
Cdc73+/− 1.932± 0.175 1.0 0.924
Kidney
Cdc73+/+ 0.371± 0.023 — —
Cdc73+/− 0.374± 0.023 1.0 0.925
Pancreas
Exocrine Cdc73+/+ 0.208± 0.032 — —
Cdc73+/− 0.293± 0.046 1.4 0.136
Endocrine Cdc73+/+ 0.363± 0.045 — —
Cdc73+/− 0.398± 0.033 1.1 0.533
Abbreviation: cdc73, cell division cycle 73. aA minimum of four animals per genotype and a minimum of four sections per animal were analysed.
Figure 3. Parathyroid tumours develop in Cdc73+/− and parathyroid-speciﬁc Cdc73+/L/PTH-Cre and Cdc73L/L/PTH-Cre knockout mice. (a–d) H&E-
stained sections of parathyroid glands from wild-type (Cdc73+/+), heterozygote (Cdc73+/− and Cdc73+/L/PTH-Cre), and homozygote (Cdc73L/L/
PTH-Cre) mice, showing: (a) homogenous histology of a wild-type parathyroid; (b) enlarged PA from a Cdc73+/− mouse; (c) a large PA from a
Cdc73+/L/PTH-Cre mouse, with increased septation and irregular outline; and (d) abnormal architecture of a parathyroid gland from a Cdc73L/L/
PTH-Cremouse, with increased lipid deposition, nodularity, necrosis and septation. (E-H) Masson’s trichrome stained sections of parathyroids of
each genotype demonstrating collagen (blue), and increased ﬁbrous septation in Cdc73+/− , Cdc73+/L/PTH-Cre and Cdc73L/L/PTH-Cre mice when
compared to Cdc73+/+ mice. (i–l) Nuclear paraﬁbromin protein expression (brown) in parathyroids was absent or reduced in Cdc73+/− , Cdc73+/
L/PTH-Cre and Cdc73L/L/PTH-Cre mice (j–l), when compared to Cdc73+/+ mice (i) (a cluster of paraﬁbromin expressing cells is indicated by the red
arrow in panel and inset). Importantly, nuclear paraﬁbromin expression was not reduced in pancreatic exocrine and exocrine cells, endothelial
cells and thyroid epithelial cells of Cdc73+/L/PTH-Cre and Cdc73L/L/PTH-Cre mice, thereby conﬁrming the parathyroid-speciﬁc loss of Cdc73
expression resulting from the presence of PTH-Cre (Supplementary Figure 3). (m–p) Galectin-3 protein expression (brown cytoplasm) in
parathyroids was increased in Cdc73+/− , Cdc73+/L/PTH-Cre and Cdc73L/L/PTH-Cre mice (n–p), when compared to Cdc73+/+ mice (m). (q–t)
Assessment of parathyroid tumour proliferation by immunoﬂuorescent BrdU incorporation, by continuous administration of BrdU in drinking
water, showing that: (q) few parathyroid cells had proliferated in Cdc73+/+ mice; but that (r–t) higher proportions of parathyroid cell nuclei had
incorporated BrdU in the parathyroid tumours of Cdc73+/− , Cdc73+/L/PTH-Cre and Cdc73L/L/PTH-Cre mice. (s) A rim of normal parathyroid tissue,
to the left of the image, had low proliferation, whilst the tumour nodule demonstrated focal areas with a high proportion of nuclei that had
incorporated BrdU. BrdU-containing nuclei (red, arrows) indicate cellular proliferation; DAPI nuclear counterstain (blue). (u–x) Assessment of
apoptosis by TUNEL assay. Apoptotic cells (green nuclei, arrows) were infrequently observed in parathyroids from mice of each genotype;
DAPI nuclear counterstain (blue). Scale bars represent 200 μm; insets have x400 magniﬁcation.
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for example, leiomyomas (uterine ﬁbroids), which are benign
smooth muscle tumours that develop in the myometrium; or both
(that is, mixed epithelial and mesenchymal) layers, for example,
carcinosarcomas which have malignant epithelial and mesench-
ymal components, and adenosarcomas which are neoplasms
composed of benign epithelium but malignant stroma.54–57 The
uterine tumours that develop in women with HPT-JT include
benign tumours such as endometrial hyperplasia, adenomyosis,
adenoﬁbromas and leiomyosis, and malignant tumours, such as
adenosarcomas.13,14 Cdc73+/− female mice devloped uterine
tumours, that were representative of those in women with HPT-
JT and these included endometrial hyperplasia, adenomyoma and
adenoﬁbroma. These uterine neoplasms developed in ~ 33% of
female Cdc73+/− mice (Figure 5), whilst spontaneous uterine
lesions were not observed in wild-type mice in our study and are
also reported to be exceedingly rare in normal wild-type mice.58
Thus, these Cdc73+/− female mice provide a model to investigate
the molecular basis of uterine tumourigenesis. A previous study of
human uterine tumorigenesis has reported 470% of Mullerian
adenosarcomas to have: copy number gain for MYB proto-
oncogene like 1 (MYBL1), mouse double minute 2 proto-oncogene
(MDM2) and cyclin dependent kinase 4 (CDK4); copy number loss
for cyclin dependent kinase inhibitor 2A (CDKN2A), breast cancer
type 1 susceptibility protein (BRCA1)-associated protein 1 (BAP1)
and RB1; single nucleotide variations including nonsense muta-
tions for TP53 and alpha thalassaemia/mental retardation syn-
drome X-linked (ATRX); and mutations in signalling pathways
notably PI3K-AKT/PTEN.59 In addition, 490% of leiomyomas
(ﬁbroids) have upregulation of G-protein coupled receptor 10
(GPR10) resulting in activation of the PI3K/AKT-mTOR pathway;54
while 70% of leiomyomas have a mutation of the mediator
complex subunit (MED12) gene60 that encodes a scaffold protein
which interacts with proteins that include β-catenin. It is
interesting to note that paraﬁbromin also directly interacts with
β-catenin in the PAF complex to mediate Wnt signalling,24 whose
dysregulation has been reported to be associated with develop-
ment of intestinal and colon cancers, and it may be that similar
pathways are involved in uterine tumourigenesis.61–63 Analysis of
mouse embryonic ﬁbroblasts from Cdc73+/+ and Cdc73-/- mice
revealed that the paraﬁbromin/PAF complex regulated genes
involved in cell growth and survival including the chromatin
remodelling genes high mobility group AT-hook 1 (Hmga1) and 2
(Hmga2) to which paraﬁbromin and PAF directly bind.19 Moreover,
paraﬁbromin may also act indirectly via HMGA1 which is a
downstream mediator of aberrant Wnt signalling.64 Thus, loss of
paraﬁbromin expression in the mouse embryonic ﬁbroblasts
of Cdc73-/- mice has been reported to lead to downregulation of
Hmga1.19 However, this role of paraﬁbromin in uterine tumour-
igenesis requires cautious extrapolation, as Hmga1 overexpression
in transgenic female mice with 1-28 copies of Hmga1a, is
associated with development of uterine tumours resembling
human uterine adenosarcomas.65,66 Finally, Wilms Tumour 1
protein (WT-1), which is often expressed in Mullerian adenosar-
coma, has been reported to bind to the CDC73 promoter and to
repress CDC73 expression in oral squamous cell carcinoma.67 The
roles of these interactions of paraﬁbromin in the aetiology of
uterine tumourigenesis remain to be explored and our establish-
ment of the Cdc73+/− mice, which develop uterine tumours, will
help to provide an important resource in these studies.
In summary, we have established a conventional Cdc73+/−
mouse, in which males and females develop PAs and APAs, and
females develop uterine tumours; thus this Cdc73+/− mouse
model is representative of the human HPT-JT syndrome.13–15
Moreover, we have developed parathyroid-speciﬁc Cdc73 knock-
out mouse models, which develop APAs and PAs. These mouse
models will facilitate further in vivo investigations of the role of
paraﬁbromin in parathyroid and uterine tumourigenesis.
Figure 4. Cdc73+/− mice have increased mean serum calcium and
PTH concentrations, when compared to Cdc73+/+ mice. (a) Serum
calcium concentration, adjusted for albumin concentration, revealed
an increased mean serum calcium concentration in Cdc73+/− mice
with parathyroid tumours when compared to Cdc73+/+ littermates
with normal parathyroids (*Po0.05). (b) Mean serum PTH concen-
tration was elevated in Cdc73+/− mice with parathyroid tumours
compared to Cdc73+/+ littermates with normal parathyroids
(*Po0.05). (c) Serum phosphate concentration in Cdc73+/− mice
with parathyroid tumours compared to Cdc73+/+ littermates with
normal parathyroids. Cdc73+/− mice with parathyroid tumours are
shown as ﬁlled symbols and Cdc73+/+ littermates with normal
parathyroids are shown as open symbols. Squares represent males
and circles represent females. The age range of the mice was
17–24 months (mean± s.e.m.= 20.0± 0.30). Combined results from
males and females for serum calcium, phosphate and PTH
concentrations are shown, as there were no signiﬁcant gender
differences. Horizontal lines indicate mean values together with the
standard error of the mean (s.e.m.), which is shown numerically
below each group and the number (N) of mice.
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MATERIALS AND METHODS
Mouse studies
The generation of the conventional and conditional Cdc73 knockout
mouse models has been previously described.19,68 Conventional Cdc73+/−
mice established using the embryonic stem cell line RRE190,19 were
maintained on a C57BL/6 background for 10 generations to obtain
congenic Cdc73+/− mice. Cdc73L/L mice19 were mated with parathyroid-
speciﬁc Cre-expressing, PTH-Cre mice,24 to generate heterozygous Cdc73+/L/
PTH-Cre mice. These Cdc73+/L/PTH-Cre mice were intercrossed to generate
three genotypes expressing the Cre-recombinase: Cdc73L/L/PTH-Cre,
Cdc73+/L/PTH-Cre, and Cdc73+/+/PTH-Cre. All mice were fed a standard diet
(RM1 expanded diet, Special Diet Services Ltd., Witham, UK) and kept in
accordance with national welfare guidelines and project license restric-
tions. Speciﬁcally, the animal studies were approved by the University of
Oxford Ethical Review Committee and were licenced under the Animal
(Scientiﬁc Procedures) Act 1986, issued by the United Kingdon Home
Ofﬁce Department (PLL 30/2914), and the Instituitional Animal Care and
Use Committee of the Van Andel Research Institute.
Cdc73+/+ and Cdc73+/− mice underwent a full post mortem at ~ 7 and
417–21 months of age, together with collection of blood samples for
serum analysis and collecting of tissues for histological analysis. Cdc73+/+/
PTH-Cre, Cdc73+/L/PTH-Cre and Cdc73L/L/PTH-Cre mice were studied at
7–12 months and ~ 20 months of age. Macroscopic and microscopic
examinations for HPT-JT associated tumours was undertaken.
Genotype studies
Genotypes of the Cdc73+/+ and Cdc73+/− mice were determined by
polymerase chain reaction (PCR) analysis of DNA using PCR primers
(f 5′-GTCACAAA ACCAAAGCCTCTGGAACG-3′, r 5′-GTTACAAGGTCATGG
ATATTTCCACC-3′ and Geor 5′-CTGCAAGGCGATTAAGTTGGGTAACG-3′) to
yield a wild-type band of 321 bp and a mutant band of 289 bp. Reverse
transcriptase-PCR (RT-PCR), using total RNA extracted from Cdc73+/+ and
Figure 5. Uterine abnormalities develop in Cdc73+/− mice. (a) H&E-stained section of a uterus from a Cdc73+/+ mouse showing a normal
myometrium (Myo), endometrium (Endo) and central lumen (l). (b, c) H&E-stained sections of uteri from Cdc73+/− mice with endometrial
hyperplasia (b) and endometrial hyperplasia with squamous metaplasia (arrows) (c). Endometrial cysts (labelled c) and mucosal bridges
traversing the lumen were observed in all the Cdc73+/− mice with neoplasms (b–e). (d) H&E-stained section of a uterine adenoﬁbroma from a
Cdc73+/− mouse with irregular polypoid endometrial projections into the lumen and cyst formation. (E) H&E-stained section of a uterine
adenomyoma with glandular endometrium and irregular endometrial polyps projecting into the lumen. (f) Immunostaining for paraﬁbromin
in a section of a uterus from a Cdc73+/+ mouse demonstrating normal endometrial expression of paraﬁbromin. (g) Paraﬁbromin-stained
sections of a uterine tumour from a Cdc73+/− mouse demonstrating reduced paraﬁbromin expression in the endometrium. (h) Section of a
uterus from a Cdc73+/+ mouse demonstrating normal expression of progesterone receptor in the endometrium. (i) Loss of endometrial
progesterone receptor expression in a uterine tumour from a Cdc73+/− mouse. (j) Immunostaining for the proliferation marker Ki-67 in a
section of a uterus from a Cdc73+/+ mouse (brown nuclei, arrows) with haemotoxylin nuclear counterstain. The interface of endometrium
(Endo) and myometrium (Myo) is indicated by a solid red line. (k) Increased nuclear Ki-67 expression was observed in the endometrium and
myometrium of uteri from Cdc73+/− mice with tumours (arrows). (l) Quantiﬁcation of Ki-67 labelling index in the endometrium and
myometrium of uteri from Cdc73+/+ mice (blue bars) and from Cdc73+/− mice with tumours (red bars) demonstrated signiﬁcantly higher
proliferation in Cdc73+/− mice (**Po0.01, ***Po0.001) compared to Cdc73+/+ mice (total (n= ) ﬁelds of view from four mice per genotype for:
Cdc73+/+ endometrium n= 79, Cdc73+/− endometrium n= 84, Cdc73+/+ myometrium n= 78, and Cdc73+/− endometrium n= 82). All scale
bars represent 100 μm; insets have 400 × magniﬁcation.
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Cdc73+/− kidneys was performed using either Cdc73-speciﬁc primers 3 f
(5′-GACCCGACCGAAAAGATCTAC-3′), 9r (5′-AGGCTGTTTTGTACGCAATGT-3′),
and rev (5′-CCCAACAGTTGCGCAGCCTG AAT-3′) to yield a wild-type band of
593 bp, or a mutant band of 500 bp, (Figure 1b), as described.69 Genotypes
of Cdc73L/L/PTH-Cre, Cdc73+/L/PTH-Cre, and Cdc73+/+/PTH-Cre mice were
determined by PCR analysis of DNA using primers to detect the presence
of LoxP and Cre-recombinase sites as previously described.19,24
Western blot analysis
Western blot analysis using total protein extracted from tissues of Cdc73+/+
and Cdc73+/− mice was performed (Figure 1c), as previously described.69
The ability of the anti-paraﬁbromin antibody to detect paraﬁbromin was
validated using siRNA targeting CDC73 (Dharmacon, Amersham, UK).
Histology and immunohistochemistry
Tissues were ﬁxed overnight in neutral buffered 4% paraformaldehyde
before embedding and sectioning for immunohistochemical analysis.
Haematoxylin and eosin staining was performed, using previously
described methods.70 Commercially available antibodies were obtained
and used according to the manufacturer’s instructions (rabbit anti-
paraﬁbromin A300-171A and anti-paraﬁbromin IHC-00379 (Bethyl,
Montgomery, TX, USA), rabbit anti-galectin-3 ab53082 (Abcam, Cambridge,
UK), rat anti-Ki-67 M7249 (Dako, Glostrup, Denmark), rabbit anti-cyclin D1
clone SP4 (Thermo, Waltham, MA, USA), and rabbit anti-retinoblastoma sc-
7905 (Santa Cruz, Heidelberg, Germany)). Colour reaction was developed
using secondary goat anti-rabbit antibody conjugated with horseradish
peroxidase (HRP) (Dako, Glostrup, Denmark) or biotinylated rabbit anti-rat
antibody and streptavidin/HRP (DakoCytomation, Glostrup, Denmark) and
3,3'-diaminobenzidine chromogen (DAB) solution (Vectashield, Peterbor-
ough, UK), and nuclei were counterstained with haematoxylin, as
previously described.70 Masson’s trichrome staining was used to assess
for collagen in parathyroid tissue, such that collagen ﬁbres were stained
blue, nuclei were stained black and muscle, cytoplasm or keratin
background was stained red/purple. Proliferation analysis was performed,
as described,31 using continuous long-term administration of 1 mg/ml
BrdU in drinking water, which speciﬁcally incorporates into the DNA of
dividing cells, and BrdU was visualized utilizing commercially available
antibodies (sheep anti-BrdU ab2285 (Abcam), Cy3-conjugated donkey anti-
sheep (Jackson, West Grove, PA, USA)), as previously reported.31 The
proportion of BrdU and Ki-67 containing nuclei was calculated from a
minimum of six slides per specimen and four animals per group. Daily
proliferation rates were expressed as the percentage of BrdU-containing
nuclei divided by the number of days of BrdU exposure, as described.31
The Ki-67 proliferation index was calculated by dividing the number of
Ki-67 labelled nuclei by the total number of nuclei, multiplied by 100, in
randomly selected ﬁelds of view (200x magniﬁcation). ApopTag in situ
apoptosis detection kit S7110 (Millipore, Billerica, MA, USA) was used
according to manufacturer’s instructions to assess for apoptotic cells
utilizing terminal deoxynucleotidyl transferase (TdT) for detection of free
3′OH DNA termini formed by DNA fragmentation, as described.31
Established criteria from the World Health Organization and other
reports,71–73 were used to distinguish between PCs, APAs and PAs.
Histologically, the diagnosis of PC requires demonstration of either
capsular, vascular, and/or perineural tumour invasion, tumour growth into
adjacent tissues, lymph node metastasis, local recurrence or distant
metastasis, while APAs have features of PCs that lack unequivocal evidence
for invasive growth.71,74 Moreover, the presence of ⩾ 4 associated features
of malignancy that include: capsular invasion without extension to
surrounding soft tissue; mitosis 45/10 high power ﬁelds; broad
intratumoural ﬁbrous bands; coagulative tumour necrosis; diffuse sheet-
like monotonous small cells with high nucleus:cytoplasmic ratio; diffuse
cellular atypia; and presence of macronuclei in many tumour cells, qualiﬁes
for a diagnosis of PC, whereas the presence of only 1–3 of these features,
qualiﬁes for a diagnosis of APA.71–73 PAs, which are benign neoplasms, do
not have any of the features and also do not have evidence of invasive
growth.
Clinical chemistry
Serum was analysed for calcium, phosphate, creatinine and albumin, as
previously described.50 Total serum calcium (Ca2+) was adjusted (ACa)
for albumin (Alb) using the formula: ACa =Ca2+ (mmol/l)− ((Alb
(g/l)− 30) × 0.017), as described.50 Serum PTH was assayed using a
commercial ELISA kit.50 Conversion to yield SI units was as follows:
Ca2+ (mmol/l) = (serum calcium in mg/dl) × 0.2495 and PO2− (mmol/
l) = (serum phosphate in mg/dl) × 0.3229.
Statistical analysis
Normally distributed data were analysed by Student’s t-test or ANOVA
followed by Tukey’s multiple comparison post-hoc test. A two-tailed
Fisher’s exact test was used for 2x2 contingency tables, and Kaplan–Meyer
analysis was performed using a two-tailed Log-rank test.50 P-values o0.05
were considered statistically signiﬁcant. Sample sizes are stated in the
results section and the ﬁgure legends. The sample size for the survival
study was selected based on a power of 80% to detect a 5% signiﬁcance
level (two-tailed) using equal numbers per group and a hazard ratio of 0.5;
no animals were excluded, randomization was not required and blinding
was not performed.
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